GlobeNewswire·Jun 14, 2026, 10:00 AM ET

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026

Upstream Bio presented new responder analyses from the Phase 2 VIBRANT trial for verekitug at the EAACI 2026 Congress in Istanbul.
Verekitug is administered once every three months to treat chronic rhinosinusitis with nasal polyps (CRSwNP).
Approximately 80% of verekitug-treated participants achieved clinically meaningful improvements in the Nasal Polyp Score (NPS), the primary endpoint.
72% of participants experienced clinically meaningful improvements in nasal congestion, while 83% improved in the total symptom score.
69% of participants showed improvement in sense of smell, and 78% demonstrated significant reduction in sinus disease extent based on the Lund-Mackay score.
The trial included 81 adults with severe, inadequately controlled CRSwNP who received 100 mg of verekitug or placebo subcutaneously every 12 weeks for 24 weeks.
Verekitug demonstrated a favorable safety profile with no serious adverse events observed during the study.
Upstream Bio plans to initiate Phase 3 registrational trials for CRSwNP and severe asthma in the first quarter of 2027.
Verekitug is the only known antagonist currently in clinical development that targets the TSLP receptor.